National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 7) (No. PB 94 of 2012) (Cth)
PB 94 of 2012
National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 7)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.
Dated 26 November 2012
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1 Name of Instrument
(1) This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 7).
(2) This Instrument may also be cited as PB 94 of 2012.
2 Commencement
This Instrument commences on 1 December 2012.
3 Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1 Amendments
Schedule 1, entry for Atenolol
omit from the column headed “Claimed Price”: 3.72 substitute: 4.24
Schedule 1, entry for Betamethasone
omit:
| Ointment 200 micrograms (as valerate) per g, 100 g | Application | Celestone-M | 1 | 7.20 | 8.19 |
Schedule 1, entry for Doxepin in the form Capsule 10 mg (as hydrochloride)
(a) omit from the column headed “Determined Price”: 2.06 substitute: 2.83
(b) omit from the column headed “Claimed Price”: 3.64 substitute: 4.41
Schedule 1, entry for Doxepin in the form Capsule 25 mg (as hydrochloride)
(a) omit from the column headed “Determined Price”: 2.41 substitute: 2.94
(b) omit from the column headed “Claimed Price”: 3.99 substitute: 4.51
Schedule 1, entry for Escitalopram in the form Tablet 10 mg (as oxalate)
omit from the column headed “Claimed Price”: 9.87 substitute: 11.26
Schedule 1, entry for Escitalopram in the form Tablet 20 mg (as oxalate)
omit from the column headed “Claimed Price”: 11.04 substitute: 13.08
Schedule 1, entry for Indapamide
omit from the column headed “Claimed Price”: 8.79 substitute: 10.46
Schedule 1, entry for Isosorbide Mononitrate
substitute:
| Isosorbide Mononitrate | Tablet 60 mg (sustained release) | Oral | Imdur Durule | 30 | 4.45 | 7.48 |
| Monodur 60 mg | 30 | 4.45 | 6.67 | |||
| Tablet 120 mg (sustained release) | Oral | Imdur 120 mg | 30 | 10.54 | 13.57 |
Schedule 1, entry for Lisinopril in the form Tablet 5 mg [Zestril]
omit from the column headed “Claimed Price”: 5.61 substitute: 7.45
Schedule 1, entry for Lisinopril in the form Tablet 10 mg [Zestril]
omit from the column headed “Claimed Price”: 7.82 substitute: 9.66
Schedule 1, entry for Lisinopril in the form Tablet 20 mg [Zestril]
omit from the column headed “Claimed Price”: 9.54 substitute: 11.38
Schedule 1, entry for Loperamide
(a) omit from the column headed “Determined Price”: 1.65 substitute: 1.39
(b) omit from the column headed “Claimed Price”: 2.37 substitute: 1.99
Schedule 1, entry for Meloxicam
substitute:
| Meloxicam | Capsule 7.5 mg | Oral | Mobic | 30 | 6.82 | 8.24 |
| Capsule 15 mg | Oral | Mobic | 30 | 9.95 | 11.37 | |
| Tablet 7.5 mg | Oral | Mobic | 30 | 6.82 | 8.24 | |
| Tablet 15 mg | Oral | Mobic | 30 | 9.95 | 11.37 |
Schedule 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 50 mg [Betaloc]
omit from the column headed “Claimed Price”: 4.78 substitute: 5.79
Schedule 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 100 mg [Betaloc]
omit from the column headed “Claimed Price”: 5.53 substitute: 6.55
Schedule 1, entry for Mirtazapine
substitute:
| Mirtazapine | Tablet 15 mg (orally disintegrating) | Oral | Avanza SolTab | 30 | 13.75 | 14.72 |
| Tablet 30 mg | Oral | Avanza | 30 | 11.96 | 14.79 | |
| Tablet 30 mg (orally disintegrating) | Oral | Avanza SolTab | 30 | 18.34 | 19.32 | |
| Tablet 45 mg | Oral | Avanza | 30 | 19.95 | 22.79 | |
| Tablet 45 mg (orally disintegrating) | Oral | Avanza SolTab | 30 | 27.64 | 28.72 |
Schedule 1, entry for Mometasone in the form Cream containing mometasone furoate 1 mg per g, 15 g
omit from the column headed “Claimed Price”: 8.05 substitute: 8.85
Schedule 1, entry for Mometasone in the form Lotion containing mometasone furoate 1 mg per g, 30 mL
omit from the column headed “Claimed Price”: 11.53 substitute: 12.34
Schedule 1, entry for Mometasone in the form Ointment containing mometasone furoate 1 mg per g, 15 g
omit from the column headed “Claimed Price”: 8.05 substitute: 8.85
Schedule 1, entry for Omeprazole
omit from the column headed “Claimed Price”: 12.82 substitute: 14.17
Schedule 1, entry for Prochlorperazine
omit from the column headed “Claimed Price”: 3.92 substitute: 4.62
Schedule 1, entry for Propranol in the form Tablet containing propranol hydrochloride 10 mg
omit from the column headed “Claimed Price”: 5.59 substitute: 6.08
Schedule 1, entry for Propranol in the form Tablet containing propranol hydrochloride 40 mg
omit from the column headed “Claimed Price”: 5.89 substitute: 6.38
Schedule 1, entry for Telmisartan in the form Tablet 40 mg
omit from the column headed “Claimed Price”: 7.89 substitute: 8.29
Schedule 1, entry for Telmisartan in the form Tablet 80 mg
omit from the column headed “Claimed Price”: 19.80 substitute: 20.21
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0